Pfizer's COVID-19 vaccine trial data shows long-term efficacy in adolescents
Pfizer Inc said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years. A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said. The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.
Reuters - November 22, 2021View the full story here: https://www.reuters.com/markets/europe/pfizers-covid-19-vaccine-shows-long-term-efficacy-trial-adolescents-2021-11-22/